Temple has acquired Longevous Global Services LTD for an undisclosed amount. The deal brings the preventative healthcare provider under Temple’s ownership, with Longevous’s operations and team set to be integrated into Temple’s existing structure. The transaction closed earlier this month, according to a joint statement from the companies.
Longevous operates in the preventative medicine space, combining academic research, advanced diagnostics, and artificial intelligence with clinical judgment to deliver anticipatory care. Its model focuses on identifying health risks before they manifest as disease, aiming to extend both lifespan and healthspan. Temple, the acquiring party, is a separate entity whose business activities will now incorporate Longevous’s diagnostic and AI-driven care capabilities.
The acquisition is driven by Temple’s interest in broadening its service offerings into proactive health management. For Temple, the purchase provides immediate access to Longevous’s established framework for integrating research-backed protocols into routine patient care. The strategic rationale centers on consolidating Longevous’s specialized approach under Temple’s operational umbrella, allowing for shared infrastructure without the need to build such capabilities from scratch.
For Longevous, the transaction offers a path to scale its model within a larger organizational context. The company’s existing client base and clinical partnerships will remain intact, but administrative and back-end functions are expected to be absorbed by Temple. No changes to Longevous’s core medical protocols have been announced, and its leadership is expected to stay in place during the transition.
The combined entity will now operate with a broader mandate, pairing Longevous’s anticipatory care model with Temple’s resources. The immediate focus will be on integrating workflows and ensuring continuity for existing patients. Over the next several quarters, the success of the acquisition will likely be measured by how smoothly Longevous’s diagnostic tools and research partnerships are maintained under new ownership.